In the years following completion of the sequencing of the human genome, the era of cancer genomics has evolved from hope to reality. However, the simplistic outlook of a decade ago has yielded a more complex and individualized approach that involves carefully choreographed harmony between basic science, computational bioinformatics, and clinical acumen. As it stands today, genomic medicine is an example of translational medicine at its very best. A recent study reported by Morganella et al. in nature communications described the sequencing of genomes of cells taken from 560 breast cancers.
[1] The genomes of tumor cells were compared to those of healthy cells from the same individual and were observed to contain thousands of mutations. The results suggest that the progression of a cell from healthy to tumor state involves multiple mutations, and they were able to cluster the breast cancers into different types based on their mutation "signatures" and their natural history of tumorigenesis. The authors, led by Serena Nik-Zainal of the Sanger Institute, Cambridge, suggest this approach may make it possible to classify breast tumors into different treatment clusters. This landmark study will help future selection of better individualized treatment and provides a roadmap for similar studies in other cancers.
The single snapshot of a tumor may not be enough, however, as elegantly shown in a collaborative European study by Yates et al. [2] All cancers arise from somatic mutations acquired by the DNA over time. However, not all somatic mutations detected in cancer may have been causative to the tumor. Mutations in cancer are generally classified into "driver" and "passenger" mutations; with driver mutations being clonally selected and key to the causative process, while the
